Comprehensive Genomic Profiling in Pediatric Peritoneal Mesothelioma

ByHolly Zink
Comprehensive Genomic Profiling in Pediatric Peritoneal Mesothelioma

Mesothelioma is a serious cancer in the lining of body cavities. It affects people of all ages. Although rare in children, it shows how dangerous it is. A recent study looks at pediatric peritoneal mesothelioma. It highlights the need for detailed genetic testing. These insights could improve treatments for older patients.

Case Report and Genomic Insights

A case report followed a 5-year-old boy with a year of painless abdominal swelling. Doctors found a large cyst in his abdomen, which they removed. Tests confirmed peritoneal mesothelioma. Genetic profiling showed no typical mesothelioma mutations. But, there were gene amplifications in AURKA, AURKC, HLA-1B, ZNF-217, OR5F1, and MEN1.

Three months after surgery, scans revealed the cancer had spread. Tragically, he died from pneumonia. This case underlines peritoneal mesothelioma’s rapid spread and the possible impact of genetic changes.

Comprehensive Genomic Profiling

Comprehensive genomic profiling (CGP) analyzes various genetic changes in tumors. These changes include mutations, amplifications, deletions, and fusions that may spur cancer growth. By pinpointing these changes, CGP reveals potential treatment targets and helps tailor personalized plans.

For older mesothelioma patients with other health issues, CGP shines. Standard treatments, like chemo and radiation, can be tough. However, targeted therapies, guided by CGP, are more exact and likely gentler.

Literature Review: A Vital Component of Medical Research

This article included a literature review. A literature review summarizes past research on a topic, highlighting gaps and providing context for new findings. In mesothelioma, it helps consolidate knowledge on the disease, its genetics, and new treatments.

For example, a review might uncover common genetic changes, effectiveness of treatments, and ongoing trials. This information is vital for researchers and doctors aiming to enhance patient outcomes with new therapies and personalized medicine.

Implications for Elderly Patients

Knowing mesothelioma’s genes helps detect it early and act quickly. This is vital for elders who might not handle tough treatments well. Personalized plans, based on genetic profiles, can improve life and lengthen it.

Mesothelioma is a scary diagnosis for all ages. Pediatric peritoneal mesothelioma, for instance, shows the need for detailed genetic testing. This testing is crucial. It identifies targets for treatment. For older patients, genetic testing also offers hope. It helps create personalized treatments. These treatments are tailored for the challenges of this aggressive disease. As research progresses, using genetic testing in clinics promises to transform mesothelioma care. It brings new hope to patients and caregivers.

Source:

Redzepagic, Jasmina, Zlatan Zvizdic, Nurija Bilalovic, Emir Milisic, Melika Bukvic, and Semir Vranic. “Comprehensive Genomic Profiling of Pediatric Peritoneal Mesothelioma: Case Report with a Literature Review.” Journal of Surgical Case Reports 2024, no. 5 (May 18, 2024): rjae324. https://doi.org/10.1093/jscr/rjae324.

Similar Posts

Mesothelioma Blood Test May Be Possible
|

Mesothelioma Blood Test May Be Possible

ByAlex Strauss

An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma
| |

Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

ByAlex Strauss

Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

Inflammation Both “Friend and Foe” in Mesothelioma
| |

Inflammation Both “Friend and Foe” in Mesothelioma

ByAlex Strauss

An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…

FDG PET-CT Results Could Lead to Improved Mesothelioma Treatment
| |

FDG PET-CT Results Could Lead to Improved Mesothelioma Treatment

ByAlex Strauss

In a recent study, researchers say a better understanding of certain diagnostic criteria could result in more targeted treatments for malignant mesothelioma. In a recent published report, doctors from the medical school at Dicle University in Diyarbakir, Turkey measured the relationship between PET-CT scan results and survival in 177 patients with malignant pleural mesothelioma. The patients were diagnosed between April 2007 and April 2011. They had a mean age of 55.4 and most (56%) were male. Patients in the study all had FDG PET-CT scans before beginning their mesothelioma treatment. FDG PET-CT scanning is a powerful imaging tool for mesothelioma and other cancers that combines a radioactive tracer with a combination of positron emission tomography and computed tomography scanning.  Because…

Mesothelioma Surgeons Report New Biopsy Technique
| |

Mesothelioma Surgeons Report New Biopsy Technique

ByAlex Strauss

A team of surgeons in Maryland have demonstrated how using a standard biopsy tool in a new way could improve the biopsy process for certain mesothelioma patients. An aggressive cancer of the pleural lining around the lungs, malignant pleural mesothelioma usually requires a tissue biopsy to make a definitive diagnosis. Often this is done using a rigid tool called a thoracoscope inserted into the chest wall while the patient is under general anesthesia. However, mesothelioma doctors at Walter Reed National Military Medical Center detail the case of a 79-year-old suspected mesothelioma patient whose biopsy was done in a minimally-invasive way, under conscious sedation, thanks to the novel use of a standard tool. Although the patient had several of the common signs…

New Serum Marker Could Improve Mesothelioma Diagnosis
|

New Serum Marker Could Improve Mesothelioma Diagnosis

ByAlex Strauss

Japanese researchers believe they have found a way to diagnose a rare form of mesothelioma earlier using a simple blood test. Diffuse malignant peritoneal mesothelioma (DMPM), which represents about a fourth of all mesothelioma cases, is an aggressive malignancy that spreads across the lining of the abdomen. In most cases, DMPM is lethal within a year. The standard treatment for diffuse malignant peritoneal mesothelioma is cytoreductive surgery to remove as much of the mesothelioma as possible, followed by intraperitoneal chemotherapy to destroy residual cancer cells. In some studies, this approach has resulted in 5-year survival rates of 30 to 60 percent. However, it is most successful when it is performed early, while the primary mesothelioma tumor is more easily removed. Like all forms of…